OHSU HOSPITAL AND CLINICS
The Sunshine Act requires manufacturers to report payments to teaching hospitals as institutions, separately from payments to individual physicians. These figures are money reported to the hospital itself — most of it research funding and grants, not compensation to any named doctor.
- Total reported
- $239.3M
- Transactions
- 20,790
- Companies
- 40
- Average per transaction
- $11,511
Who reported the payments
| Merck | $29,506,110 |
| AstraZeneca | $16,319,569 |
| Novartis | $13,033,594 |
| AbbVie | $10,267,831 |
| Deciphera Pharmaceuticals Inc. | $9,616,090 |
| Janssen Research & Development, LLC | $8,592,337 |
| Regeneron | $8,369,423 |
| Novo Nordisk AS | $7,600,375 |
| Edwards Lifesciences | $6,317,586 |
| E.r. Squibb & Sons, L.L.C. | $6,063,919 |
| Beigene, Ltd. | $5,698,463 |
| Pfizer | $5,639,763 |
| Incyte Corporation | $5,154,304 |
| Eli Lilly | $5,015,489 |
| Gilead | $4,447,906 |
| Genentech, Inc. | $4,066,070 |
| Biogen | $4,032,360 |
| CSL Behring | $3,788,717 |
| Amgen | $3,592,794 |
| Medtronic | $3,351,799 |
| Vertex | $2,675,233 |
| Astrazeneca UK Limited | $2,362,269 |
| Takeda Pharmaceuticals U.S.A., Inc. | $2,305,846 |
| Seagen Inc. | $2,281,782 |
| Otsuka Pharmaceutical Co., Ltd. | $2,239,710 |
| Bristol Myers Squibb | $2,106,114 |
| Sanofi | $2,018,593 |
| Jazz Pharmaceuticals Inc. | $1,969,160 |
| Servier Bioinnovation | $1,855,043 |
| Eisai Inc. | $1,807,793 |
| Dexcom, Inc. | $1,704,060 |
| Exelixis Inc. | $1,689,220 |
| Astellas Pharma Global Development | $1,624,741 |
| Roche TCRC, Inc. | $1,553,875 |
| EMD Serono, Inc. | $1,434,711 |
| Sanofi US Services Inc. | $1,401,217 |
| Boehringer Ingelheim | $1,332,596 |
| Blueprint Medicines Corporation | $1,298,846 |
| Insmed, Inc. | $1,271,684 |
| AMAG Pharmaceuticals, Inc. | $1,263,394 |